aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$61.99M

FY 2025 · Annual

Investing Cash Flow

-$5.05M

FY 2025 · Annual

Financing Cash Flow

$66.01M

FY 2025 · Annual

+65.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
Deferred Income Tax00000
Stock-Based Compensation1.61M2.15M2.6M2.99M5M
Change in Working Capital(2.59M)(833K)15.01M(6.92M)7.45M
Accounts Receivables1.6M(11.92M)9.05M402K863K
Inventory00000
Accounts Payables47K03.26M(1.34M)(33K)
Other Working Capital(4.24M)11.09M2.7M(5.98M)6.62M
Other Non-Cash Items363K441K(3.19M)(2.71M)(1.87M)
Operating Cash Flow(33.08M)(41.89M)(33.22M)(69.12M)(61.99M)
Capital Expenditures(192K)(1.64M)(4.22M)(65K)(77K)
Acquisitions (Net)50K007K12K
Purchases of Investments(126.51M)(42.12M)(106.98M)(69.1M)(93.45M)
Sales of Investments35.08M90.83M91.05M86.39M86.6M
Other Investing Activities0179K15K01.85M
Investing Cash Flow(91.57M)47.25M(20.13M)17.23M(5.05M)
Debt Repayment0(66K)(394K)(497K)(539K)
Common Stock Issued109.95M5.47M66.52M40.26M66.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities73K45K105K100K0
Financing Cash Flow110.03M5.45M66.23M39.86M66.01M
Effect of Forex Changes00000
Net Change in Cash(14.62M)10.81M12.88M(12.02M)(1.03M)
Free Cash Flow(33.27M)(43.53M)(37.44M)(69.18M)(62.06M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$74.1M
+ D&A$1.6M
+ Stock-Based Comp$5.0M
+ Deferred Tax$0
+ Working Capital$7.5M
- Other Non-Cash-$1.9M
= Operating Cash Flow-$62.0M
- Capex-$77.0K
= Free Cash Flow-$62.1M

Analysis

FY2025 free cash flow is -$62.1M. FCF conversion is 83.7% of net income. Operating cash flow was -$62.0M, with capex of -$77.0K. The largest bridge item is Working Capital at $7.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-8S-8 filingAug 7, 2026
8-KCurrent reportAug 7, 2026
10-QQuarterly reportAug 7, 2026
SC 13G/ASC 13G/A filingAug 6, 2026
8-KCurrent reportJul 31, 2026

Does ATYR generate free cash flow?

aTyr Pharma, Inc. (ATYR) generated -$62.06M of free cash flow in fiscal 2025.

How much operating cash flow does ATYR produce?

Operating cash flow was -$61.99M, before capital expenditures of $77,000.00.